Asset
ZOLDONRASIB
REVOLUTION MEDICINES INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07777822 | phase3 | recruiting | 2026-08-14 | 2029-10-01 | Revolution Medicines, Inc. | Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC |
| NCT07397338 | phase1_2 | recruiting | 2026-01-30 | 2029-05-01 | Revolution Medicines, Inc. | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors |
| NCT06162221 | phase1_2 | recruiting | 2024-01-18 | 2027-06-01 | Revolution Medicines, Inc. | Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC |
| NCT06445062 | phase1_2 | recruiting | 2024-05-24 | 2028-09-30 | Revolution Medicines, Inc. | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors |
| NCT06040541 | phase1 | recruiting | 2023-09-07 | 2026-12-31 | Revolution Medicines, Inc. | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors |
FDA applications (0)
This company has no applications containing this asset.